Value
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 5.7 |
| P/S | 10.0 |
| EV/EBITDA | 3.9 |
| Fwd P/E | 8.0 |
| PEG | 9.2 |
| Analyst target | 5.0 |
- ▸Forward P/E: 15.0x
- ▸PEG: 0.63
- ▸Attractively valued
COR · Why this verdict
Why Cencora (COR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Two value-trap signals are present simultaneously: operating margin has compressed to -30.1% and the debt-to-equity ratio sits at 1.5; a company with deeply compressed margins and meaningful leverage that also screens cheap on price multiples may be inexpensive for structural rather than cyclical reasons. Bear case | Operating margin should stabilize or expand toward positive territory over the next 2 quarters, and leverage should decline toward 1.0x debt-to-equity; failure on either dimension would confirm the value-trap reading. | →Stable |
| CounterMedical distribution businesses often operate on very thin margins with elevated leverage given the capital-intensity of the model; the margin compression may reflect mix shifts or one-time charges rather than a deteriorating competitive position. | ||
The company's overall business quality falls well below the minimum acceptable floor, with no discernible competitive moat, a Piotroski financial strength score of 4.4 out of 9, and multiple quality concerns flagged — making this a business whose apparent cheapness may not compensate for the structural weakness of its fundamentals. Warnings | Over 12 months, operating margin should show a sustained improvement trend and the Piotroski financial strength score should rise above 6 out of 9; a failure of these metrics to improve would confirm the quality concern is structural rather than temporary. | →Stable |
| CounterA Piotroski score of 4.4 is not catastrophically low, and the company has executed a perfect four-quarter beat streak with modest but consistent surprises; if earnings execution continues, the quality perception may improve alongside the results. | ||
Free cash flow is negative — converting at -12% relative to net income — meaning the company is not translating its reported earnings into cash; this is a significant quality red flag that undermines the reported profitability of the business. Quality breakdown | Free cash flow should turn positive within the next 2 quarters; sustained negative free cash flow after two additional reporting periods would indicate the conversion problem is structural rather than cyclical. | →Stable |
| CounterNegative free cash flow in a distribution business can reflect a temporary inventory or working-capital build tied to contract onboarding rather than an underlying earnings-quality problem; if the working-capital cycle normalizes, free cash flow may recover quickly. | ||
The top ten customers account for approximately 66% of revenue; this concentrated revenue base means that the loss, renegotiation, or financial stress of even a handful of key accounts could materially impair the top line. Bear case | The top ten customer revenue contribution should remain stable or decline as a percentage of total revenue over 12 months; any customer departure within this group that results in more than a 5% revenue decline would confirm the concentration risk. | →Stable |
| CounterHigh customer concentration in medical distribution often reflects long-term contractual relationships with large health systems or pharmacy chains that are difficult to unwind; the sticky nature of these contracts may make the concentration less fragile than it appears. | ||
Two value-trap signals are present simultaneously: operating margin has compressed to -30.1% and the debt-to-equity ratio sits at 1.5; a company with deeply compressed margins and meaningful leverage that also screens cheap on price multiples may be inexpensive for structural rather than cyclical reasons.
→StableBear case
- Expectation
- Operating margin should stabilize or expand toward positive territory over the next 2 quarters, and leverage should decline toward 1.0x debt-to-equity; failure on either dimension would confirm the value-trap reading.
CounterMedical distribution businesses often operate on very thin margins with elevated leverage given the capital-intensity of the model; the margin compression may reflect mix shifts or one-time charges rather than a deteriorating competitive position.
The company's overall business quality falls well below the minimum acceptable floor, with no discernible competitive moat, a Piotroski financial strength score of 4.4 out of 9, and multiple quality concerns flagged — making this a business whose apparent cheapness may not compensate for the structural weakness of its fundamentals.
→StableWarnings
- Expectation
- Over 12 months, operating margin should show a sustained improvement trend and the Piotroski financial strength score should rise above 6 out of 9; a failure of these metrics to improve would confirm the quality concern is structural rather than temporary.
CounterA Piotroski score of 4.4 is not catastrophically low, and the company has executed a perfect four-quarter beat streak with modest but consistent surprises; if earnings execution continues, the quality perception may improve alongside the results.
Free cash flow is negative — converting at -12% relative to net income — meaning the company is not translating its reported earnings into cash; this is a significant quality red flag that undermines the reported profitability of the business.
→StableQuality breakdown
- Expectation
- Free cash flow should turn positive within the next 2 quarters; sustained negative free cash flow after two additional reporting periods would indicate the conversion problem is structural rather than cyclical.
CounterNegative free cash flow in a distribution business can reflect a temporary inventory or working-capital build tied to contract onboarding rather than an underlying earnings-quality problem; if the working-capital cycle normalizes, free cash flow may recover quickly.
The top ten customers account for approximately 66% of revenue; this concentrated revenue base means that the loss, renegotiation, or financial stress of even a handful of key accounts could materially impair the top line.
→StableBear case
- Expectation
- The top ten customer revenue contribution should remain stable or decline as a percentage of total revenue over 12 months; any customer departure within this group that results in more than a 5% revenue decline would confirm the concentration risk.
CounterHigh customer concentration in medical distribution often reflects long-term contractual relationships with large health systems or pharmacy chains that are difficult to unwind; the sticky nature of these contracts may make the concentration less fragile than it appears.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Cencora's quality profile sits below the minimum acceptable threshold — free cash flow is negative, margins have compressed sharply to -30.1%, and leverage is elevated — while a perfect four-quarter beat streak and 8.4% upside to the analyst target create a tension between business-quality concerns and near-term earnings execution.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 2.3 |
| Gross margin | 0.0 |
| Op margin | 0.7 |
| Net margin | 0.4 |
| Current ratio | 3.8 |
| FCF quality | 0.0 |
| Moat | 4.9 |
| Piotroski F | 4.4 |
- ▸Excellent ROE: 107%
- ▸Earnings quality RED FLAG: -12% FCF/NI
- ▸No competitive moat
- ▸Quality concerns
Growth
6.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
| EPS growth | 10.0 |
Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.5 |
| Volume | 5.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.1 |
| Price target | 7.4 |
| erm sentiment | 4.5 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider buying — $2,310,426 (0.004% of mkt cap)
Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.5 |
| quality rank | 4.6 |
| growth rank | 2.0 |
Technical
2.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.5 |
| 52w position | 5.9 |
Risk (lower is worse)
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.2 |
| days to cover | 6.8 |
| volatility | 6.1 |
| put call | 3.3 |
| implied vol | 5.9 |
| max pain risk | 3.0 |
| beta | 9.5 |
| debt equity | 0.8 |
- ▸Above max pain $175
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 3.4 |
| dividend safety | 5.2 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 81.0%
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.2<1.5@spot
Warning (2)
- DEATH_CROSS:momentum=7.0>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.23
Upside
+2.3%
Downside
9.8%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 67
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.1 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.2<1.5@spot.
The strongest dimensions are Value at 7.1, Momentum at 7.0, and Growth at 6.8; the weakest are Technical at 2.1, Quality at 2.9, and Peer rank at 4.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.23 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Minimum Threshold
Trip ifOperating margin turns positive AND gross margin expands above 3% for 3 consecutive quarters, indicating a genuine quality recovery.
- P2Negative Free Cash Flow Red Flag
Trip ifFree cash flow rises above $0 for 2 consecutive quarters, demonstrating that reported earnings have begun converting into cash.
- P3Value Trap Margin Compression Leverage
Trip ifDebt-to-equity falls below 1.0 AND operating margin expands above 2% for 2 consecutive quarters.
- P4Customer Concentration Top Ten
Trip ifTop ten customer revenue concentration falls below 50% of total revenue for 2 consecutive quarters.